The Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS) first approved Allergan, Inc.’s Botox® product, botulinum toxin type A, for treatment of glabellar lines in 2003. Allergan, Inc. markets its Botox® product in France under the product name Vistabel®, which was licenced for the same use in the U.K. in March 2006. At […]
As dermatological technology advances, simple cosmetic treatments such as facial fillers and Botox are no longer primarily targeted for women. Men are increasingly taking advantage of cosmetic enhancements as well, to help fight signs of age and to increase professional marketability. Men looking for an affordable alternative to invasive cosmetic surgery are turning to facial […]
Botox, an incredibly popular drug sold by Allergan Inc., is used primarily in cosmetic procedures designed to reduce facial wrinkles and is derived from the deadly botulinum neurotoxin produced by the bacteria clostridium botulinum. A different version of botulinum neurotoxin, known as Myobloc, is used in medical procedures designed to reduce muscle stiffness and spasms […]
For the first time ever, an attempt has been made to monitor and control places that provide Botox treatments and “filler” injections. With 5,000 clinics performing approximately 200,000 Botox treatments for wrinkles and filler treatments designed to plump lips and sagging skin each year in the United Kingdom, the industry is in dire need of […]
